Skip to main content
Premium Trial:

Request an Annual Quote

Abbott to Develop Companion Dx for Epizyme Cancer Drug Candidate

NEW YORK (GenomeWeb News) – Epizyme today said that Abbott will develop a molecular companion diagnostic test for a leukemia drug candidate that the Cambridge, Mass.-based firm is developing.

Abbott will develop a test based on its fluorescence in situ hybridization technology to detect genetic alterations of mixed lineage leukemia, an aggressive subtype of acute myeloid leukemia and acute lymphoblastic leukemia.

Epizyme is developing an inhibitor targeting the DOT1L histone methyltransferase for the treatment of mixed lineage leukemia and will use the Abbott test to detect MLL genetic alterations that lead to the oncogenic function of DOT1L.

Further terms of the alliance were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.